- Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC.
- Ryan C.
- OncLive. 2022 Oct 3.
- News
- Free Full Text
Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2022 Oct 5.)
- A First-in-Class Clinical G-Quadruplex-Targeting Drug. The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
- Xu H, Hurley LH.
- Bioorg Med Chem Lett. 2022 Oct 1:129016. doi: 10.1016/j.bmcl.2022.129016. Epub ahead of print.
- PMID: 36195286
- PubMed abstract
- Source abstract
- Review
Original research:
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
- PMID: 35750695
- PubMed abstract
- Free Full Text
Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov)